株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

オーファンドラッグの世界市場:2019年~2023年

Orphan Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 906373
出版日 ページ情報 英文 172 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
オーファンドラッグの世界市場:2019年~2023年 Orphan Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023
出版日: 2019年08月13日 ページ情報: 英文 172 Pages
概要

世界のオーファンドラッグ市場は、強力なパイプラインや最新の医薬品承認、希少疾患の発生率の増加、オーファンドラッグ開発のインセンティブの有効性などが成長促進要因となり、予測期間中に約12%のCAGRで拡大する見込みです。ただし、診断の遅れ、新規オーファンドラッグの臨床開発に伴うリスク、オーファンドラッグの価格設定と償還に伴う課題などの不安定要素により、予測期間中のオーファンドラッグ産業の成長が妨げられる可能性があります。

当レポートでは、世界のオーファンドラッグ市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 パイプライン分析

第7章 市場セグメンテーション化:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • 生物製剤
  • 非生物製剤
  • 市場機会:製品別

第8章 顧客情勢

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第10章 意思決定の枠組み

第11章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第12章 市場動向

  • アライアンス、パートナーシップ、M&Aに戦略的に焦点を当てる
  • 併用療法と新しい標的の出現
  • 遺伝子検査とタンパク質バイオマーカーに対する需要の高まり

第13章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競争シナリオ

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • 武田薬品工業

第15章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第16章 TECHNAVIOについて

図表
  • Exhibit 01: Recent mega-mergers in pharmaceuticals
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Some of the first-in-class orphan drugs approved by the US FDA during 2017-2018
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Some of the late-stage orphan drugs
  • Exhibit 20: Product - Market share 2018-2023 (%)
  • Exhibit 21: Comparison by product
  • Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 23: Number of new or expanded indications approved for novel orphan biologics to the number of rare and non-rare diseases from the US FDA January 2013-June 2019
  • Exhibit 24: Promising regenerative orphan drugs pricing plans
  • Exhibit 25: Biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Non-biologics - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 27: Non-biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Market opportunity by product
  • Exhibit 29: Customer landscape
  • Exhibit 30: Market share by geography 2018-2023 (%)
  • Exhibit 31: Geographic comparison
  • Exhibit 32: North America - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 33: Number of orphan drug approvals in US 2014-2018
  • Exhibit 34: US FDA orphan drug marketing approvals in major therapeutic areas 2008-2017
  • Exhibit 35: List of expensive orphan drugs launched in US
  • Exhibit 36: Leading vendors and their product sales in US 2018.
  • Exhibit 37: Status of BTD, PR, and ODD for novel drugs 2013-2017
  • Exhibit 38: RMAT designation requests by product type 2018
  • Exhibit 39: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Europe - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 41: Orphan drug approvals in Europe during 2010-2018
  • Exhibit 42: Applications for ODD in EU 2005-2018
  • Exhibit 43: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 44: Asia - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 45: Orphan drugs eligible for reimbursable under China's state health insurance schemes
  • Exhibit 46: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 47: ROW - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 48: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 49: Key leading countries
  • Exhibit 50: Market opportunity
  • Exhibit 51: List of promising drugs approved in US, Japan, and EU 2017-2019
  • Exhibit 52: Number of orphan drugs approved in US, EU, and Japan 2017 and 2018
  • Exhibit 53: Percentage of orphan and non-orphan drugs approved by the US FDA 2018
  • Exhibit 54: Incidence rate of rare diseases per year in US
  • Exhibit 55: Prevalence of rare diseases 2018 (millions)
  • Exhibit 56: Orphan drugs regulatory framework and incentives in key leading regions or countries
  • Exhibit 57: Impact of drivers and challenges
  • Exhibit 58: Several major M&A in the market
  • Exhibit 59: Expansion of combination therapies research areas of ICI approved drugs
  • Exhibit 60: Ongoing immunotherapy combinations studies with co-inhibitory molecules
  • Exhibit 61: Ongoing immunotherapy combinations studies with co-stimulatory molecules
  • Exhibit 62: Vendor landscape
  • Exhibit 63: Landscape disruption
  • Exhibit 64: Vendors covered
  • Exhibit 65: Vendor classification
  • Exhibit 66: Market positioning of vendors
  • Exhibit 67: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 68: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 69: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 70: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 71: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 72: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 77: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 78: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 79: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 80: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 81: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 82: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 83: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 84: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 85: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 86: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 87: Novartis AG - Vendor overview
  • Exhibit 88: Novartis AG - Business segments
  • Exhibit 89: Novartis AG - Organizational developments
  • Exhibit 90: Novartis AG - Geographic focus
  • Exhibit 91: Novartis AG - Segment focus
  • Exhibit 92: Novartis AG - Key offerings
  • Exhibit 93: Novartis AG - Key customers
  • Exhibit 94: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 95: Takeda Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 96: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 97: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 98: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 99: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 100: Validation techniques employed for market sizing
  • Exhibit 101: Definition of market positioning of vendors
目次
Product Code: IRTNTR31893

About this market

Technavio's orphan drugs market analysis considers sales from both biologics and non-biologics. Our analysis also considers the sales of orphan drugs in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high efficacy will play a significant role in the biologics segment to maintain its market position. Also, our global orphan drugs market report looks at factors such as robust pipeline and recent drug approvals, rising incidence of the rare disease, availability of incentives for orphan drug development. However, uncertainties in the delay in diagnosis, risks associated with the clinical development of novel orphan drugs and challenges associated with pricing and reimbursements for orphan drugs may hamper the growth of the orphan drugs industry over the forecast period.

Overview

Rising incidence of rare diseases

Orphan drugs are specifically used to treat rare diseases, and the prevalence of such health conditions has a direct influence on the sales of orphan drugs. Rare diseases include inherited genetic disorders, rare types of cancer, tropical infectious diseases, and neurodegenerative diseases. The prevalence and distribution of rare diseases are skewed. Although some rare diseases are inherited, others are a product of harmful environmental factors. This will lead to the expansion of the global orphan drugs market at a CAGR of almost 12% during the forecast period.

The emergence of combination therapies and novel targets

The potential advances in several areas such as immunotherapies and CGT are rekindling interest and enabling progress in the development of orphan drugs. These advances have been made in target selection, and combination therapy approaches for effectively reversing the immunosuppressive mechanisms, thereby enhancing the durability of the therapeutics. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global orphan drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global orphan drugs market is moderately fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading orphan drugs manufacturers, that include Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Takeda Pharmaceutical Co. Ltd.

Also, the orphan drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Biologics - Market size and forecast 2018-2023
  • Non-biologics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
  • PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Strategic focus on alliances, partnerships, and M&A
  • Emergence of combination therapies and novel targets
  • Rising demand for genetic tests and protein biomarkers

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Takeda Pharmaceutical Co. Ltd.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

Back to Top